Monocytes to Apolipoprotein A1 Ratio is Associated with Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Mellitus

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 29

PMID 39733102

Authors

Wei Wang

Lian Huang

Xiu Ping Qiu

Mei Tu

Xiu Li Guo

Affiliations

Soon will be listed here.

Abstract

The monocyte-to-Apolipoprotein A1 ratio (MAR) emerges as a potentially valuable inflammatory biomarker indicative of metabolic dysfunction-associated fatty liver disease (MASLD). Accordingly, this investigation primarily aims to assess the correlation between MAR and MASLD risk. A cohort comprising 957 individuals diagnosed with type 2 diabetes mellitus (T2DM) participated in this study. The relationship between MAR and MASLD was analyzed through binomial logistic regression analysis and restricted cubic splines (RCS). Furthermore, a comparative assessment of MAR and monocyte to high-density lipoprotein ratio (MHR) in identifying MASLD efficacy was conducted using receiver operating characteristic curve analysis. Remarkably, even after adjusting for metabolic parameters and hepatic functional markers, MAR stood out as an independent predictor for MASLD (OR 1.58, 95% CI 1.36-1.84; P < 0.001) and displayed a nonlinear positive association with MASLD risk according to RCS analysis (P for nonlinearity and overall < 0.001). Notably, MAR exhibited superior diagnostic accuracy for identifying MASLD compared to MHR (AUC: 0.772 vs 0.722, P < 0.001). In summary, MAR emerges as a promising inflammatory indicator for MASLD, demonstrating potential as a valuable screening tool to bolster the management of MASLD within the T2DM population.

References

Shi C, Pamer E . Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011; 11(11):762-74. PMC: 3947780. DOI: 10.1038/nri3070. View

Ampuero J, Aller R, Gallego-Duran R, Banales J, Crespo J, Garcia-Monzon C . The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018; 48(11-12):1260-1270. DOI: 10.1111/apt.15015. View

Arrese M, Cabrera D, Kalergis A, Feldstein A . Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci. 2016; 61(5):1294-303. PMC: 4948286. DOI: 10.1007/s10620-016-4049-x. View

Jung U, Choi M . Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014; 15(4):6184-223. PMC: 4013623. DOI: 10.3390/ijms15046184. View

Sorci-Thomas M, Thomas M . Why targeting HDL should work as a therapeutic tool, but has not. J Cardiovasc Pharmacol. 2013; 62(3):239-46. PMC: 3772973. DOI: 10.1097/FJC.0b013e31829d48a5. View

Huang H, Wang Q, Shi X, Chen Y, Shen C, Zhang J . Association between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Mediators Inflamm. 2021; 2021:6642246. PMC: 8670965. DOI: 10.1155/2021/6642246. View

Barreby E, Chen P, Aouadi M . Macrophage functional diversity in NAFLD - more than inflammation. Nat Rev Endocrinol. 2022; 18(8):461-472. DOI: 10.1038/s41574-022-00675-6. View

Kim H, Jeon H, Choi H, Kwon I, Rou W, Lee J . CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease. BMC Gastroenterol. 2023; 23(1):77. PMC: 10022198. DOI: 10.1186/s12876-023-02717-3. View

Jackson A, Rahman G, Long S . Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspective. Mol Cell Biochem. 2021; 476(8):3065-3078. DOI: 10.1007/s11010-020-04037-6. View

10.

Wang W, Chen Z, Guo X, Tu M . Monocyte to High-Density lipoprotein and Apolipoprotein A1 Ratios: Novel Indicators for Metabolic Syndrome in Chinese Newly Diagnosed Type 2 Diabetes. Front Endocrinol (Lausanne). 2022; 13:935776. PMC: 9330493. DOI: 10.3389/fendo.2022.935776. View

11.

Krenkel O, Puengel T, Govaere O, Abdallah A, Mossanen J, Kohlhepp M . Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2017; 67(4):1270-1283. DOI: 10.1002/hep.29544. View

12.

Deprince A, Haas J, Staels B . Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020; 42:101092. PMC: 7600388. DOI: 10.1016/j.molmet.2020.101092. View

13.

Jia J, Liu R, Wei W, Yu F, Yu X, Shen Y . Monocyte to High-Density Lipoprotein Cholesterol Ratio at the Nexus of Type 2 Diabetes Mellitus Patients With Metabolic-Associated Fatty Liver Disease. Front Physiol. 2022; 12:762242. PMC: 8718696. DOI: 10.3389/fphys.2021.762242. View

14.

Bonora E, Targher G, Alberiche M, Bonadonna R, Saggiani F, Zenere M . Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23(1):57-63. DOI: 10.2337/diacare.23.1.57. View

15.

Kim H, Chung G, Park I, Choi J, Hwang S, Lee J . Elevated peripheral blood monocyte fraction in nonalcoholic fatty liver disease. Tohoku J Exp Med. 2011; 223(3):227-33. DOI: 10.1620/tjem.223.227. View

16.

Wang X, Rao H, Zhao J, Wee A, Li X, Fei R . STING expression in monocyte-derived macrophages is associated with the progression of liver inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Lab Invest. 2019; 100(4):542-552. DOI: 10.1038/s41374-019-0342-6. View

17.

Ozanska A, Szymczak D, Rybka J . Pattern of human monocyte subpopulations in health and disease. Scand J Immunol. 2020; 92(1):e12883. DOI: 10.1111/sji.12883. View

18.

Nati M, Chung K, Chavakis T . The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease. J Innate Immun. 2021; 14(1):31-41. PMC: 8787511. DOI: 10.1159/000518407. View

19.

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79(6):1542-1556. DOI: 10.1016/j.jhep.2023.06.003. View

20.

Bril F, McPhaul M, Caulfield M, Clark V, Soldevilla-Pico C, Firpi-Morell R . Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. Diabetes Care. 2019; 43(2):290-297. DOI: 10.2337/dc19-1071. View